Dong De-qiong, Yang Yu-hao, Xue Dong-ying, Feng Xian-jun
Department of Respiratory Medicine, Affiliated Hospital of Zunyi Medical College, Guizhou Zunyi, 563003, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006 Dec;31(6):848-52.
To determine the diagnostic value of the expression of survivin mRNA in sputum samples and pleural effusions in lung cancer.
The sputum samples of 104 patients with lung cancer and 30 patients with chronic obstructive pulmonary disease (COPD), and the pleural effusion of 56 patients with lung cancer and 30 patients with tuberculosis pleural effusions were detected.Reverse transcription-polymerase chain reaction (RT-PCR) was performed to detect the survivin mRNA expression in the specimens. The results were compared with their cytological examinations.
The sensitivity of the cytological examinations combined with the detection of survivin mRNA in sputum samples was higher than that of either cytological examination or survivin mRNA detection of sputum samples alone (P<0.01). The sensitivity of the diagnosis for lung cancer increased from 37.5% (sputum cytology alone) to 78.8% (sputum survivin mRNA detection combined with sputum cytology) (P<0.01), and the negative predictive value increased from 31.6% (sputum cytology alone) to 43.5% (sputum survivin mRNA detection combined with sputum cytology) (P<0.01). The sensitivity of the cytological examinations combined with the detection of survivin mRNA in pleural effusion samples was higher than that of cytological examination of pleural effusion samples alone (P<0.01). The sensitivity of the diagnosis for lung cancer increased from 42.9% (pleural effusion cytology alone) to 80.4% (pleural effusion survivin mRNA detection combined with cytology) (P<0.01), and the negative predictive value increased from 48.4% (pleural effusion cytology alone) to 77.8% (pleural effusion survivin mRNA detection combined with cytology) (P<0.01).
The detection of survivin mRNA from sputum samples and pleural effusions samples is a new diagnostic method for lung cancer.
确定survivin mRNA在肺癌患者痰液样本及胸腔积液中的表达情况对肺癌的诊断价值。
检测104例肺癌患者及30例慢性阻塞性肺疾病（COPD）患者的痰液样本，以及56例肺癌患者及30例结核性胸腔积液患者的胸腔积液。采用逆转录聚合酶链反应（RT-PCR）检测标本中survivin mRNA的表达，并将结果与其细胞学检查结果进行比较。
痰液样本中细胞学检查联合survivin mRNA检测的敏感性高于单独的细胞学检查或单独的survivin mRNA检测（P<0.01）。肺癌诊断的敏感性从37.5%（单纯痰液细胞学检查）提高到78.8%（痰液survivin mRNA检测联合痰液细胞学检查）（P<0.01），阴性预测值从31.6%（单纯痰液细胞学检查）提高到43.5%（痰液survivin mRNA检测联合痰液细胞学检查）（P<0.01）。胸腔积液样本中细胞学检查联合survivin mRNA检测的敏感性高于单独的胸腔积液细胞学检查（P<0.01）。肺癌诊断的敏感性从42.9%（单纯胸腔积液细胞学检查）提高到80.4%（胸腔积液survivin mRNA检测联合细胞学检查）（P<0.01），阴性预测值从48.4%（单纯胸腔积液细胞学检查）提高到77.8%（胸腔积液survivin mRNA检测联合细胞学检查）（P<0.01）。
检测痰液样本及胸腔积液样本中的survivin mRNA是一种新的肺癌诊断方法。
